Skip to main content
. 2009 Dec 2;9:420. doi: 10.1186/1471-2407-9-420

Figure 2.

Figure 2

Effect of chemotherapy and the TP53 mutation in colorectal cancer patients of Dukes' stage C. (a): Overall survival of Dukes' stage C patients with the TP53 mutation and without the mutation (n = 62, P = 0.891). (b): Overall survival of patients with surgical treatment alone and with postoperative chemotherapy (n = 62, P = 0.037). Patients at Dukes' stage C with the TP53 mutation did not show significant sensitivity to chemotherapy (c) (n = 11, P = 0.727), but patients with the TP53 mutation show a significant effect of chemotherapy (d)(n = 51, P = 0.026).